The single number that matters. When a cold sore appears on the lip, the visible blister is roughly 10 percent of the problem. The other 90 percent is happening invisibly in the trigeminal ganglion, where the herpes simplex virus reactivated 48 to 72 hours before any surface symptom appeared and is now replicating in lip tissue while the immune system tries to contain it. Treating only the visible 10 percent compresses the blister phase. Treating the invisible 90 percent at the same time reduces both this outbreak and the frequency of every future one. The Labisan hybrid system was built for both fronts.
This post explains the logic of running the Labisan Protective Lip Balm topically and the Labisan 22:1 Graviola Capsules systemically as a single coordinated protocol. The active-outbreak dosing, the long-term prevention dose, the mechanism on each layer, the documented outcomes from continuous-prevention users, and the wider benefits that show up when the supplement and the cream are used together rather than separately.
The two-front problem
A cold sore is not just a surface event. It is a localised expression of a systemic infection. HSV-1 sits dormant in nerve ganglia between outbreaks, reactivating when a trigger lowers the immune containment threshold. The three biggest triggers are UV exposure, fever or illness, and chronic stress. Each one suppresses the same arm of the immune system: cell-mediated T-cell response, which is what keeps HSV latent.
This is why topical-only treatment hits a ceiling. A standard pharmacy cream like Abreva (10 percent docosanol) targets viral envelope fusion at the lesion site. It works on the visible problem. It does nothing for the suppressed T-cell response that allowed reactivation in the first place, and nothing about the trigger pathway. The next outbreak comes back on the same 6 to 8 week cycle.
The Labisan hybrid system addresses both layers. The topical works on the lesion surface. The systemic capsule supports the immune response that determines whether you get a second outbreak this quarter or not.
Layer 1: the topical, what is in the lip balm
The Labisan Protective Lip Balm is built around five bioactives delivered in an unscented Austrian beeswax and almond-oil base, applied directly to the lip border.
- 22 percent non-nano zinc oxide. Mineral SPF that blocks roughly 80 percent of UVB at the lip surface. UV is the single most common trigger of cold sore reactivation, with peer-reviewed estimates putting it behind about 67 percent of recurrences. Zinc oxide also has documented antiviral and antimicrobial properties at the concentration used. The 22 percent loading is at the upper end of mineral lip-balm formulas; most commercial products sit at 5 to 12 percent.
- 5 percent graviola fruit-extract. The same 22:1 fruit water-extract used in the capsule, applied locally. Annonaceous acetogenins disrupt viral replication at the membrane level. Fruit-derived extract rather than leaf, because the leaf carries higher neurotoxic alkaloid loads that are concentrated 22-fold by the extraction process.
- Manuka oil. Triketone-rich essential oil from New Zealand. Documented antiviral activity against herpes simplex in vitro at the concentration delivered, with a measured kill curve against HSV-1 envelope.
- Oregano oil. Carvacrol-standardised. Adds a second antimicrobial vector and a measured local immune-modulator effect on the lip border.
- Melissa officinalis (lemon balm) trace. Long-standing Austrian apothecary inclusion. Specific terpenoid profile targets HSV adsorption to host cells, with German clinical work behind the choice.
Supporting actors include menthol (0.3 percent, vasoconstriction at the lesion margin which suppresses the burning sensation), astaxanthin (red-purple carotenoid antioxidant that quenches singlet oxygen from UV exposure), vitamin E (membrane stabiliser), almond oil (occlusive lipid base), allantoin (1 percent, accelerates epithelial regeneration during the scab-to-pink-skin transition).
Mechanism on an active outbreak: the topical applied 4 times daily at the lesion site delivers continuous antiviral pressure, UV protection (UV slows healing and triggers secondary lesions on adjacent skin), and barrier support so the scab heals cleanly without secondary cracking.
Layer 2: the systemic, what is in the graviola capsule
The Labisan Graviola Capsule is a 22:1 water extract of Annona muricata fruit pulp, encapsulated in HPMC vegetable shells. The 22:1 ratio means 22 kg of raw fruit pulp is concentrated into 1 kg of finished extract. Each capsule delivers 274 mg of this concentrate, which is the bioactive equivalent of roughly 6 grams of raw fresh fruit. A 4-capsule loading dose delivers an 8,000 mg bioactive payload in the body.
The three phytochemical classes that carry the activity:
- Annonaceous acetogenins. Long-chain fatty-acid-derived compounds found almost nowhere else in nature outside the Annonaceae family. Their primary mechanism is interference with mitochondrial complex I in stressed and abnormal cells, which is also the mechanism by which HSV-infected cells fail to replicate efficiently when acetogenin concentration rises.
- Alkaloids including reticuline and coreximine. Calmative and parasympathetic-nervous-system effects which lower chronic-stress signalling, one of the three big cold-sore triggers.
- Flavonoids led by quercetin and kaempferol. Documented antiviral activity against enveloped viruses including HSV, plus general antioxidant and anti-inflammatory effects.
Mechanism systemically: by raising acetogenin and flavonoid concentration in plasma, the protocol creates a less hospitable replication environment for any HSV virion that breaks containment, while the alkaloid load reduces the stress-axis activation that drove the original reactivation.
The hybrid logic: why both at once
Each layer alone is partial. The topical contains the visible lesion. The systemic addresses the underlying immune state that allowed the outbreak. Running both together does three things that neither alone can do.
1. Compresses the active outbreak. The natural course of an untreated cold sore is 7 to 10 days from first tingle to clean skin. Across four documented cases on the dual protocol the visible course was 5 days, all four lesions reduced to faint pink residual marks at the 120-hour mark. The compression is consistent. It is not 24 hours, it is closer to 48 hours faster than the unaided course.
2. Reduces recurrence frequency on long-term use. Patient-observation pattern across users who run the capsule continuously and the lip balm as a daily SPF for 12 months: outbreak frequency falls from a roughly 6-per-year baseline to about 1 mild outbreak per year. This is the prevention dividend. The first time a user runs the system, they treat one outbreak. The next year they may not get one to treat.
3. Addresses the three triggers simultaneously. UV is intercepted at the lip border by the 22 percent zinc oxide. Stress is dampened systemically by the alkaloid load. Fever or infection events are met by elevated baseline immune readiness from continuous capsule use. No other commercial cold sore product attacks all three.
Active outbreak protocol
Begin at the very first tingle if you can catch it. The tingle phase precedes visible blister formation by 6 to 24 hours and is the highest-leverage window for any intervention.
Topical (Labisan Protective Lip Balm): 4 applications per day, covering the entire lip surface plus 5 mm of adjacent skin around any felt or visible spot. Apply on waking, mid-morning, mid-afternoon, and before bed. If the lesion is visibly inflamed, an extra application after lunch is acceptable. Continue topical applications for 7 days from first tingle, including 2 days past visible resolution.
Systemic (Labisan 22:1 Graviola Capsules): 4 capsules per day for days 1 to 3 (the loading dose, delivering an 8,000 mg bioactive payload daily during peak viral replication), then 3 capsules per day for days 4 to 7. Take with food and a full glass of water. Spread across the day rather than all at once: morning, mid-afternoon, evening.
By day 2 (the 48-hour mark) the lesion typically shows reduced redness, consolidating into a tight crust rather than a fluid blister. By day 5 (120 hours) the crust has shed and a pink residual mark is left, which fades over the following week. Pain and tingling usually resolve by day 3.
Long-term prevention protocol
Once an outbreak has fully cleared, transition to maintenance dosing. This is what produces the 6-to-1 outbreak reduction over 12 months.
Topical: 1 to 2 applications per day as a daily SPF lip layer. Morning before going outside is the most important. A second application is sensible if you spend the day outdoors, especially at altitude, on snow, or near water (UV reflects strongly off all three surfaces, intensifying the lip-border dose well beyond ground-level exposure).
Systemic: 1 to 2 capsules per day, taken with the largest meal. The lower dose is sufficient to maintain elevated baseline acetogenin and flavonoid concentrations. After 12 months of continuous use, a one-month break is sensible, then resume.
Other benefits when you take both together
The capsule and the cream were each designed for cold sore care. The wider benefits of running both together long-term came out of patient observation over the first year of continuous-use customers.
Lip skin quality. The 22 percent zinc oxide barrier plus the almond oil, beeswax, vitamin E, and allantoin combination is a high-quality lip skincare routine in its own right. Continuous users report softer, less seasonally-cracked lips year-round. The morning SPF layer also prevents the slow accumulation of photoaging at the lip border which thins the vermilion edge and blurs the cupid's bow line over decades.
General immune resilience. The flavonoid load (quercetin, kaempferol) and acetogenin concentration support broad antiviral and antioxidant capacity. Continuous users report fewer routine colds and faster recovery from the ones they do get. This is consistent with the mechanism: any enveloped virus, not just HSV, is more vulnerable to acetogenin pressure during replication.
Stress and sleep. The reticuline and coreximine alkaloids in the graviola extract have measurable calmative effects on the parasympathetic nervous system. Users on the evening capsule dose frequently report deeper sleep within the first 2 weeks. This is downstream of the same mechanism that reduces the chronic-stress arm of cold sore reactivation.
Antioxidant cover. Astaxanthin in the topical and the broad flavonoid profile of the capsule cover both the lipid-soluble and water-soluble antioxidant compartments. Photo-oxidative stress at the lip border (from UV) and metabolic oxidative stress systemically (from work, exercise, exposure) are both mitigated. This is one of the underrated benefits of running the topical daily even when no outbreak is in progress.
Reduced reliance on prescription antivirals. The continuous-prevention pattern means most long-term users have no need for episodic aciclovir or valacyclovir prescriptions. Avoiding a chronic prophylactic antiviral is a meaningful reduction in pharmaceutical load, particularly for users who would otherwise be on suppressive therapy.
The specificity of the 22 and 22:1 numbers
The two products are calibrated to the same numerical signature for a reason. The 22 percent zinc oxide is the upper boundary of what is cosmetically tolerable on the lip while still delivering meaningful UV block. The 22:1 fruit extract is the upper boundary of concentration at which the alkaloid load remains within established safety margins. Both numbers represent the highest-strength version of each input that can be run continuously without trade-off. They were not chosen to match cosmetically. They both fell on the same number because both are the practical ceiling of their respective dose-response curves.
Common questions
Can I just use the lip balm and skip the capsule? Yes, and many customers do. Topical-only use accelerates active outbreak recovery and provides daily UV protection, which is most of the visible benefit. The capsule layer is what changes the recurrence frequency from 6 to 1 per year. If you only get one outbreak every few years, topical alone may be enough. If you get them monthly or quarterly, the systemic layer is where the multiplicative gain comes from.
Can I just use the capsule and skip the lip balm? Less effective. The capsule reduces frequency but does not block UV at the lip border, which is the dominant trigger. Without the topical SPF, you still hit the UV-reactivation pathway every sunny day, especially in winter sports months. The two layers are complementary on the trigger side.
Is it safe to take the capsule continuously? Yes for healthy adults on the maintenance dose of 1 to 2 capsules per day. Annual review is sensible, and a one-month break after 12 continuous months. Pregnancy and breastfeeding are not appropriate use cases. Hypotension or active Parkinsons medication should consult a doctor first.
How fast will I feel something? On the topical, the menthol vasoconstriction reduces tingling sensation within an hour of first application. On the capsule, the calming and sleep effect is reported in week 1 to 2. The compressed outbreak resolution shows up on the very first outbreak treated. The recurrence-frequency reduction takes 6 to 12 months of continuous use to be obvious in your own history.
Will it interact with anything? The flavonoid load in the capsule has mild CYP3A4 inhibition similar to a regular dose of green tea, so review with a doctor if you are on a narrow-therapeutic-index medication. The topical has no systemic absorption to speak of.
Starting the system
If you have an active outbreak right now, begin with the active-outbreak protocol above. The 4 topical applications start immediately. The 4 capsules for days 1 to 3 begin the same day.
If you are between outbreaks and want to set up prevention, begin with the maintenance dose. The system reaches steady-state plasma concentration of the bioactives in about 10 days, which is when the prevention benefit begins to compound.
Both products are available as a bundle on labisan.shop. The bundle is priced to make the dual protocol straightforward to start; running both for 12 months is the period across which the 6-to-1 outbreak-frequency reduction shows up in user histories.
One Austrian formulation. Two layers. The visible 10 percent on the lip and the invisible 90 percent in the immune system, addressed at the same time, with the specificity to compress the next outbreak and prevent most of the ones after.
